Evidence map›Paper›PMID 42154134›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

GMP-compliant automated synthesis and quality control of [

Amélie Coussirou, Mélodie Six, Agathe Edet-Sanson, Alice Salles, Pierre Vera, David Tonnelet, Pierre Bohn

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amélie CoussirouService de Médecine Nucléaire, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France. amelie.coussirou@chb.unicancer.fr.
Mélodie SixService de Médecine Nucléaire, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.
Agathe Edet-SansonService de Médecine Nucléaire, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.
Alice SallesService de Médecine Nucléaire, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.
Pierre VeraService de Médecine Nucléaire, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.
David TonneletService de Médecine Nucléaire, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.
Pierre BohnService de Médecine Nucléaire, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France. pierre.bohn@chb.unicancer.fr.ORCID http://orcid.org/0000-0001-8972-9022

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PCa) has been identified as the most prevalent form of cancer among males and the third leading cause of death from cancer in the European male population. Early-stage PCa can be treated with prostatectomy and radiotherapy, whereas metastatic cases require androgen deprivation therapy and may benefit from targeted radionuclide therapy (TRT). The objective of our research is to develop and validate an automated production of [

resultsThis work delineates the development and validation of analytical methodologies for the automated production of [

conclusionsThe findings of this study underscore the potential of [

Indexed as

Experimental drugLutetiumProstate cancerPSMA-I&TRadioligand therapy

Identifiers

PMID42154134
PMCPMC13357460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.